Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Sep 05, 2018 10:46am

110 Views

Post# 28565158

RE:RE:Kwang Dong

The largest pharma in SK is yuhan which has a market cap 8X kwang dong but both companies have quite similar sales. As is the case in SK, companies favour conglomarates so kwang dong sell pharma, foods, water, nutrients and as such has a very different P/E.

Kwang dong has been manufacturing and selling pharma since 1950's.

I think its safe to say they are a credible (and sizeable) SK pharma.

Thats what my brief research this morning is telling me anyway.

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload